Antibe Therapeutics' Lead Drug Shows Promising Effects in Alveolar Bone Loss Study
Business Wire - Thu Oct 08, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company"
ATE.VN: 0.170 (-0.010)
IIROC Trade Resumption - Antibe Therapeutics Inc.
Newsfile Corp - Tue Oct 06, 10:29AM CDT
Trading resumes in:
Antibe Therapeutics Announces Strategic Transactions
Business Wire - Tue Oct 06, 10:15AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company"
ATE.VN: 0.170 (-0.010)
IIROC Trade Halt - Antibe Therapeutics Inc.
Newsfile Corp - Tue Oct 06, 7:04AM CDT
The following issues have been halted by IIROC:
Colorectal Cancer - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colorectal Cancer
M2 - Fri Aug 14, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvsdxp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Key Topics Covered: - Colorectal Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Angiogene Pharmaceuticals Limited - Antibe Therapeutics, Inc. - Aphios Corporation - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Bayer AG - Beta Cat Pharmaceuticals, LLC - Biocon Limited - Bionomics Limited - BioNovion B.V. - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company For more information visit http://www.researchandmarkets.com/research/dv...tal_cancer
ADXS: 11.07 (+0.83), ARQL: 2.04 (+0.05), AMGN: 149.59 (-0.31), BMY: 61.44 (+0.93), ATNM: 2.29 (+0.10), AZN: 32.23 (-0.16), AVEO: 1.27 (+0.05), ABBV: 55.64 (-0.40), ARRY: 5.09 (+0.13)
Antibe Announces Completion of Phase I Studies of ATB-346 and an Update on Its Validation Studies
Business Wire - Mon Aug 10, 6:00AM CDT
Antibe Therapeutics Inc. ("Antibe"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Reports Year-End Financial and Operating Results
Business Wire - Tue Jul 28, 6:45PM CDT
Antibe Therapeutics Inc. ("Antibe"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Announces Addition of Aspirin Derivative to Its Product Pipeline and Provides an Update on Validation Studies
Business Wire - Mon Jul 20, 12:30PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Announces Change in CFO Position and Granting of Employee Stock Options
Business Wire - Mon Jul 13, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company"
ATE.VN: 0.170 (-0.010)
Osteoarthritis Pain Pipeline Report 2015 - 26 Companies & 46 Drug Profiles
M2 - Fri Jul 10, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8bmth/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - Astellas Pharma Inc. - Boehringer Ingelheim GmbH - Bone Medical Limited - Eli Lilly and Company - Flexion Therapeutics, Inc. - Grunenthal GmbH - iCeutica, Inc. - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (lidocaine tetracaine) - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - cebranopadol - celecoxib - CGS-125 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - ibuprofen - LY-2951742 - meloxicam - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A - oxycodone ER For more information visit http://www.researchandmarkets.com/research/w8...oarthritis
FLXN: 15.19 (+0.27), PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), AMPE: 3.04 (+0.05), LLY: 86.14 (+2.37), NKTR: 11.34 (+0.56), TEVA: 58.96 (-0.28), ABBV: 55.64 (-0.40), POZN: 6.29 (+0.10), REGN: 503.92 (+12.71)
Global Acute Pain Pipeline Report 2015
M2 - Thu Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gndxls/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt plc - MEDRx Co., Ltd. - Merck & Co., Inc. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Rottapharm SpA - Santen Pharmaceutical Co., Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. - Thar Pharmaceuticals, Inc. - Trevena, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/gndxls/acute_pain
ACRX: 3.64 (+0.17), TRVN: 10.13 (+0.26), KMPH: 18.83 (-0.18), MRK: 50.95 (-0.07), PCRX: 42.18 (+1.68), NKTR: 11.34 (+0.56)
Antibe Therapeutics Announces Administrative Items and Congratulates Dr. John Wallace on Publication in Nature Reviews
Business Wire - Tue May 05, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Announces Additional Validation Data on ATB-346
Business Wire - Fri Apr 17, 6:45AM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Company"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,250,000
Business Wire - Thu Apr 09, 11:08PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Raises $786,000 in First Tranche of Non-Brokered Private Placement
Business Wire - Wed Apr 01, 9:15PM CDT
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Provides an Update on Its Data Review and Corporate Strategy
Business Wire - Wed Mar 11, 7:21AM CDT
Antibe Therapeutics Inc. ("Antibe"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Announces No Material Change
Business Wire - Wed Feb 04, 6:45PM CST
Antibe Therapeutics Inc. ("Antibe"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Suspends Its Phase I Clinical Trial Due to Safety Concerns
Business Wire - Fri Jan 16, 6:45AM CST
Antibe Therapeutics Inc. (TSXV:ATE; OTCQX:ATBPF) today announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial.
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Announces Appointment of Canadian Rheumatologist J. Carter Thorne to Its Clinical Advisory Board
Business Wire - Thu Dec 18, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
ATE.VN: 0.170 (-0.010)
Antibe Therapeutics Announces Appointment of US-Based Investor Relations Consultant
Business Wire - Tue Dec 16, 6:45AM CST
Antibe Therapeutics Inc. ("Antibe" or the "Corporation"
ATE.VN: 0.170 (-0.010)